EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer

Xinyu Li, Tao Huang

Breast Cancer · 2025

DOI: 10.1007/s12282-025-01779-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Breast Cancer, 2025. Verfasst von Xinyu Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Rd., Wu…. Hauptthemen laut MEDLINE: Breast Neoplasms, Signal Transduction, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hormone receptor-positive (HR +) and HER2-positive (HER2+) breast cancers represent a biologically unique subset of breast malignancies characterized by the co-expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). These cancers exhibit distinct molecular features, often leading to aggressive growth and higher recurrence rates. HR+/HER2+ breast cancer cells can utilize estrogen and HER2-driven signaling pathways to promote proliferation, survival, and metastatic potential, presenting unique challenges and opportunities for treatment. The current therapeutic strategies focus on a combination of endocrine therapies, such as selective estrogen receptor modulators (e.g., tamoxifen) or aromatase inhibitors, with HER2-targeted therapies like trastuzumab, pertuzumab, or tyrosine kinase inhibitors, to concurrently inhibit both hormone and HER2-driven pathways. Despite initial treatment efficacy, resistance often develops through various mechanisms, including mutations in the PIK3CA gene, cross-talk between ER and HER2 signaling, and activation of alternative growth pathways. Ongoing research aims to improve patient outcomes by exploring novel combination therapies, including CDK4/6 inhibitors and PI3K/AKT/mTOR pathway inhibitors, and by targeting resistance pathways. This review highlights the molecular basis, treatment approaches, and emerging therapeutic strategies in HR+/HER2+ breast cancer, emphasizing the need for personalized and adaptive treatment strategies in managing this complex disease subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSignal TransductionErb-b2 Receptor Tyrosine KinasesHumansFemaleReceptors, EstrogenReceptors, ProgesteroneAntineoplastic Combined Chemotherapy ProtocolsMolecular Targeted TherapyDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Breast cancerCrosstalkEndocrine therapyEstrogen receptorHER2Target therapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, human

Autor:innen und Institutionen

  • Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Rd., Wuhan, 430022, People's Republic of China.
  • Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Rd., Wuhan, 430022, People's Republic of China. huangtaowh@163.com.

Zitieren

APA

Li, X., & Huang, T. (2025). Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer. Breast Cancer. https://doi.org/10.1007/s12282-025-01779-3

Vancouver

Li X, Huang T. Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer. Breast Cancer. 2025. doi:10.1007/s12282-025-01779-3

BibTeX
@article{Li2025,
  author = {Li, Xinyu and Huang, Tao},
  title = {Advances in the intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer},
  journal = {Breast Cancer},
  year = {2025},
  doi = {10.1007/s12282-025-01779-3}
}
Kostenlos starten →